LDS/Medical Tests/TGFB2 Gene Mutation Analysis

TGFB2 Gene Mutation Analysis

The TGFB2 gene isw located on the long (q) arm of chromosome 1 at position 41 and encodes for transforming growth factor beta-2 (TGFβ-2) protein. TGFβ-2 protein is found throughout the body but is especially abundant in the skeleton and extracellular matrix. This protein takes part in TGF-β signaling pathway and controls the proliferation, differentiation, motility and apoptosis of cells. The TGFβ-2 protein also plays a role in the formation of blood vessels, the regulation of muscle tissue, body fat development, wound healing, and immune system function.

Mutation in TGFB2 gene is associated with Loeys-Dietz syndrome type 4 (LDS4), which is an autosomal dominant disorder that affects connective tissues. Clinically, LDS4 is characterized by cleft palate, bifid uvula, hypertelorism tall stature, arachnodactyly, pectus deformity, clubfoot, osteoarthritis, aortic root anerysm, arterial aneurysms, arterial tortuosity, arterial dissection, bicuspid aortic valve, mitral valve insufficiency, straie and dural ectasia. Patients with LDS are at increased risk for aortic aneurysms, aortic dissection, intercranial aneurysms and intercranial bleeding. Mutations in TGFB2 gene cause the production of a TGFβ-2 protein that results in a gain-of-function in the TGF-β signaling pathway. This excessive signaling pathway disrupts development of connective tissue and various body systems and leads to the signs and symptoms of Loeys-Dietz syndrome type IV.

  • For the diagnosis of TGFB2-associated Loeys-Dietz syndrome type IV
  • To identify carrier of the familial TGFB2 mutation by predictive testing in family members
  • To assist with prognosis, clinical management and surveillance for disease features based on the genetic variant involved

Positive: Mutation or pathogenic variant in TGFB2 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutation or pathogenic variant in TGFB2 gene

Sequence analysis by next generation sequencing or bi-directional sequencing. SMAD2 gene -targeted deletion/duplication analysis by quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood (EDTA), amniotic fluid (prenatal test).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
]Cardiac panel, TGFBR1, TGFBR2, FBN1, ACTA2 and MYH11 mutation analysis for aortic aneurysms and aortic dissections, Comprehensive Skeletal Dysplasias and Disorders Panel, Ehlers-Danlos Syndrome Panel, Marfan Syndrome Panel, Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel, Craniosynostosis Panel, Aortopathy Panel, TGFB2 Sequencing and Deletion/Duplication analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Hum Mutat. 2018; 39: 621–634. [PMID: 29392890]
  • BMC Med Genet. 2014;15: 91. [PMID: 25163805]
  • Clin Genet. 2017 Mar;91(3):458-462. [PMID: 27440102]
  • Cell Tissue Res. 2012;347: 21-36. [PMID: 21643690]
  • Nat Genet. 2012;44:922-7. [PMID: 22772368]
  • Loeys-Dietz Syndrome. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1993-2019. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1133/.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login